India to receive between 190-250 mn fully subsidised Covid vaccines: Gavi

Photo: Shutterstock

Gavi, a global alliance on vaccines, on Friday said that India would receive between 190 and 250 million fully subsidised doses of COVID-19 vaccine and funds up to USD 30 million for urgent technical assistance and cold chain equipment.

A decision on the matter was taken by the COVAX Board in December, a Gavi spokesperson said.

Gavi, previously called Global Alliance for Vaccines and Immunisation is a publicprivate global health partnership which is leading the global effort to provide vaccines to low- and middle-income countries.

Gavi commits its full support to helping India come through its current crisis. In December 2020, the COVAX Board agreed that India would receive approximately 20 per cent of the total doses available to AMC (Advance Market Commitment)- eligible countries through the COVAX Facility estimated at between 190 and 250 million fully-subsidised doses subject to vaccine prices and available funds, a Gavi spokesperson told PTI.

"India is also to receive 20 per cent of the total funding available to AMC- eligible countries for urgent technical assistance and cold chain equipment, or USD 30 million," the spokesperson said.

Responding to a question, Gavi acknowledged that the current crisis in India has impacted its vaccine supply chain given that the country has been a major producer and supplier of vaccines.

Much of COVAX's second quarter supplies were due to be fulfilled by the Serum Institute of India (SII). As SII focuses production towards domestic needs, this has inevitably led to a shortfall for other parts of the world, the spokesperson said.

As a result, COVAX is aiming to address this in the very short term by securing dose donations from high income economies that have a surplus, as well as working towards other short-medium term goals such as diversifying its portfolio of suppliers and decreasing bottlenecks that are currently hampering global production increases, the spokesperson noted.

Gavi welcomed the decision by the United States government to use all mechanisms to increase global equitable access to COVID-19 vaccines.

We also recognise the significance of the (Biden) administration's commitment to work towards increasing raw material production which will have an immediate impact on alleviating current global supply constraints, the spokesperson said.

It is important now that in the interests of global equitable access, that the US supports manufacturers to transfer not only IP but also know-how in a bid to urgently boost global production, said the spokesperson.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel